Mesothelioma, Malignant Mesothelioma, Mesothelioma International Symposium

Alfacell Corporation will present at the Second International Symposium on Malignant Mesothelioma, to be held in Las Vegas from October 6-8, 2005.

The presentation, entitled, "Two ONCONASE(R) Clinical Trials in Malignant Mesothelioma Patients Evaluated Using the EORTC Prognostic Model," will analyze whether there is a difference in survival between ONCONASE study patients categorized as 'Good' or 'Poor' risk for survival, using European Organization for the Research and Treatment of Cancer (EORTC) prognostic scores. The EORTC model was recently validated in a study from St. Bartholomew's Hospital (Lung Cancer and Mesothelioma Unit, Medical Oncology) and The London Lung Cancer Group -- both based in London, UK -- published in the Journal of Clinical Oncology (Volume 23:1, January 1, 2005).

Alfacell, along with companies such as Eli Lilly, Merck and Fujirebio Diagnostics, has provided an educational grant in support of the symposium, which is organized by the Mesothelioma Applied Research Foundation (MARF), a national nonprofit organization dedicated to eradicating mesothelioma as a life-threatening disease.

Alfacell Corporation, 4 Oct. 2005

Mesothelioma Attorneys